EIKN
Eikon Therapeutics, Inc. Common Stock
NASDAQ: EIKN · HEALTHCARE · BIOTECHNOLOGY
$9.62
+5.54% today
Updated 2026-04-30
Market cap
$522.71M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.18
Dividend yield
—
52W range
$9 – $17
Volume
0.4M
Eikon Therapeutics, Inc. Common Stock (EIKN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| R&D | $207.26M | $204.54M | $250.32M |
| SG&A | $58.48M | $55.81M | $88.63M |
| Operating income | $-265.74M | $-260.34M | $-338.94M |
| Operating margin | — | — | — |
| EBITDA | — | — | — |
| EBITDA margin | — | — | — |
| EBIT | — | — | — |
| Interest expense | $39000.00 | $31000.00 | $837000.00 |
| Income tax | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% |
| Net income | $-242.00M | $-243.81M | $-324.25M |
| Net income growth (YoY) | — | -0.8% | -33.0% |
| Profit margin | — | — | — |